←
JAMA51,708 posts
JAMA avatar

JAMA

@JAMA_current

JAMA is an international peer-reviewed general medical journal published weekly online and in print, and a member of the @JAMANetwork family of journals.

◷ Joined May 2009▧ 13,847 Photos and videos
JAMA avatar
JAMA@JAMA_current·2h

Yesterday, the Pan American Health Organization announced the United States has lost its #measles elimination status. The setback comes after years of increasing #vaccine hesitancy. At the same time, vaccines have experienced great advancements with breakthroughs like #mRNA technology. In this episode of Healthy Dialogue, Paul Offit, MD, Director of the Vaccine Education Center at Children's Hospital of Philadelphia, discusses the history of vaccines and vaccine hesitancy, and what he sees for the future of the field. 📌 Read more: ja.ma/4zTW7l1

1:25
JAMA avatar
JAMA@JAMA_current·3h

🎧 What does the history of #VaccineHesitancy indicate about the current #Measles resurgence and concerns about messenger RNA vaccines? In the latest episode of the Healthy Dialogue podcast, host Derek Angus, MD, MPH, and Paul Offit, MD, discusses decades of vaccine misinformation, including claims about diphtheria-pertussis-tetanus, measles-mumps-rubella, and messenger RNA vaccines, and discusses how declining vaccination rates may contribute to the return of vaccine-preventable diseases. The episode also addresses the policy context surrounding vaccine confidence and access. ja.ma/4jnAcN3

JAMA avatar
JAMA@JAMA_current·4h

Use of #BloodBasedBiomarkers for #AlzheimerDisease in US clinical practice increased rapidly from Q1 2025 to Q2 2026 in a nationwide electronic health record analysis. Most test orders were for phosphorylated tau, most were placed in outpatient or laboratory settings, and more than 90% of patients had documented dementia or cognitive symptoms before testing, consistent with use in symptomatic patients. ja.ma/4zukRz8

Post attachment
JAMA avatar
JAMA@JAMA_current·4h

💡 JAMA Insights: #VaccineHesitancy is often shaped by fear, autonomy, prior experiences, and misinformation rather than by lack of information alone. This JAMA Insights describes a 4-step empathetic refutational interview that helps clinicians identify patients’ concerns, affirm underlying values, correct misconceptions, and provide clear information about #Vaccination. ja.ma/4eL1zy6

Post attachment
JAMA avatar
JAMA@JAMA_current·4h

Now that the US has lost its #measles elimination status, what should #clinicians keep top of mind? Early recognition, immediate airborne isolation, appropriate testing, postexposure management, and strong #vaccine advocacy are all critical as measles reemerges in the US. 🔗 Learn more in this JAMA Insights: ja.ma/4fCiVNS

Post attachment
JAMA avatar
JAMA@JAMA_current·6h

How does the environment contribute to the #obesity epidemic? Experts attending the #JAMASummit on Obesity noted changes in composition and availability of food, as well as differences based on socioeconomic status. 📌Read the full report: ja.ma/4t7umTl

2:25
JAMA avatar
JAMA@JAMA_current·Nov 17

🧵 Among patients with early #ParkinsonDisease, treatment with nicotinamide riboside for 52 weeks did not improve clinical outcomes vs placebo and was associated with worse change in overall Movement Disorder Society Unified Parkinson Disease Rating Scale scores. These findings do not support nicotinamide riboside as a disease-modifying treatment for Parkinson disease. ja.ma/4zTRLKL

Post attachment
JAMA avatar
JAMA@JAMA_current·Nov 17

💡 JAMA Insights: #Metabolic dysfunction-associated steatotic liver disease (#MASLD) is the most common cause of chronic #LiverDisease in children and adolescents worldwide and is often asymptomatic. This JAMA Insights indicates that screening with annual alanine aminotransferase testing starting at age 10 years is recommended for children with #obesity and for some children with #overweight or other #cardiometabolic risk factors, which may support earlier diagnosis and referral. ja.ma/4iLDqtJ

Post attachment
JAMA avatar
JAMA@JAMA_current·Nov 17

💬 Editor's Note by JAMA Associate Editor Deborah Wexler, MD, MSc, and JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS: With 1.1 billion people worldwide affected by #Obesity, newer glucagon-like peptide-1 and multiple receptor agonist therapies have changed the field, but access, adverse effects, and integration into broader strategies addressing biological, behavioral, socioeconomic, and environmental factors remain limited. This call for papers on the future of obesity seeks timely and novel research articles and opinion manuscripts on topics ranging from novel therapeutics to prevention and sustainable, comprehensive care. 🔗 Learn more: ja.ma/4zvfVdA

Post attachment
JAMA avatar
JAMA@JAMA_current·Nov 17

Join JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, and leading experts in #obesity research, treatment, and policy for an inside look at Toward a Healthier Future: The #JAMASummit Report on Obesity. Featuring report authors Derek Angus, MD, MPH, Lotte Bjerre Knudsen, DMSc, Robert Kushner, MD, MS, and Marion Nestle, PhD, MPH, this discussion will examine the most important insights, debates, and priorities emerging from the Summit and explore what it will take to achieve meaningful progress in obesity prevention and treatment over the next 1-2 years. The webinar will also include a live Q&A session with the panelists. ➡️ Register now: ja.ma/4kXaG2p

Post attachment
JAMA avatar
JAMA@JAMA_current·Nov 17

Today, JAMA published Toward a Healthier Future Through Obesity Prevention and Care: The #JAMASummit Report on Obesity. The report highlights the significant opportunity presented by the emergence of effective #obesity management medications to help curb the prevalence of obesity while emphasizing that no single intervention will be sufficient to address this complex disease. 🔗 Read the full report: ja.ma/3WJvVuJ #ObesityWeek #OW2026 @ObesitySociety

Post attachment
JAMA avatar
JAMA@JAMA_current·Nov 17

💬 Editor's Note by JAMA Statistical Editor Patrick Heagerty, PhD, and Senior Statistical Editor Roger Lewis, MD, PhD: In #RandomizedClinicalTrials, treatment policy estimands address the effect of choosing one treatment over another despite treatment discontinuation or other intercurrent events, while hypothetical estimands assess outcomes under an inferred scenario in which those events did not occur. Distinguishing these approaches can improve clinical interpretation because one informs treatment choice in practice and the other reflects a best-case efficacy scenario. ja.ma/4t4VN0j #ObesityWeek #OW2026 @ObesitySociety

Post attachment
JAMA avatar
JAMA@JAMA_current·Nov 17

💬 Editorial by William Heerman, MD, MPH, Lilianna Suarez, MD, MPH, and Sarah Armstrong, MD: #PediatricObesity pharmacotherapy has shifted from limited treatment options to multiple effective choices, with tirzepatide adding substantial BMI reduction to behavioral treatment in adolescents with obesity. Clinical care now requires individualized medication selection, dose escalation, and monitoring rather than routine escalation to the maximum tolerated dose. ja.ma/4zK6jwf #ObesityWeek #OW2026 @ObesitySociety

Post attachment
JAMA avatar
JAMA@JAMA_current·Nov 17

Among adolescents with #Obesity or overweight with obesity-related complications, once-weekly tirzepatide plus healthy lifestyle intervention led to greater reductions in #BMI vs placebo over 72 weeks. Tirzepatide was also associated with improvements in body weight, waist circumference, and physical functioning, supporting its potential clinical relevance for adolescent obesity treatment. ja.ma/4zQkTT7 #ObesityWeek #OW2026 @ObesitySociety

Post attachment